In recent years, gonadotropin releasing hormone antagonist (GnRH-ant) protocol has been widely used among PCOS patients, due to its short stimulation duration, low gonadotropin consumption and significantly lower incidence of ovarian hyperstimulation syndrome (OHSS) [24]. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.